Sangamo BioSciences Inc. (NASDAQ:SGMO)’s share price was up 4.1% during trading on Thursday . The company traded as high as $5.86 and last traded at $5.86, with a volume of 331,513 shares. The stock had previously closed at $5.63.

A number of equities analysts recently commented on SGMO shares. Wells Fargo & Co. started coverage on shares of Sangamo BioSciences in a research note on Tuesday, May 3rd. They set a “buy” rating for the company. Jefferies Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Sangamo BioSciences in a research note on Thursday, June 9th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Sangamo BioSciences in a research note on Friday, May 6th. Finally, Zacks Investment Research cut shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 5th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $16.75.

The company’s market capitalization is $406.74 million. The stock’s 50 day moving average is $6.01 and its 200-day moving average is $6.14.

Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.01. During the same quarter in the prior year, the company posted ($0.08) earnings per share. The company had revenue of $3.94 million for the quarter, compared to analyst estimates of $5.49 million. The business’s revenue was down 70.8% on a year-over-year basis. Equities analysts anticipate that Sangamo BioSciences Inc. will post ($0.98) earnings per share for the current year.

An institutional investor recently raised its position in Sangamo BioSciences stock. California State Teachers Retirement System boosted its stake in Sangamo BioSciences Inc. (NASDAQ:SGMO) by 1.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 128,941 shares of the biopharmaceutical company’s stock after buying an additional 2,257 shares during the period. California State Teachers Retirement System owned 0.18% of Sangamo BioSciences worth $1,177,000 as of its most recent SEC filing.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.